Skip to Main content Skip to Navigation
Journal articles

What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database: A compliance analysis using the French health insurance database

Abstract : The inherent risk of agranulocytosis associated with clozapine requires the realization of weekly white blood cell monitoring (WBCM) during the 18 first weeks of treatment. The aim of this study was to assess the compliance with WBCM during clozapine initiation for schizophrenia and Parkinson's disease (PD) subjects.
Document type :
Journal articles
Complete list of metadata

https://hal-univ-tours.archives-ouvertes.fr/hal-03406940
Contributor : Martine Augouvernaire Connect in order to contact the contributor
Submitted on : Thursday, October 28, 2021 - 10:48:49 AM
Last modification on : Friday, October 29, 2021 - 3:22:29 AM

Identifiers

Citation

Edouard-Jules Laforgue, Marion Istvan, Marylène Guerlais, Anicet Chaslerie, Pascal Artarit, et al.. What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database: A compliance analysis using the French health insurance database. Expert Opinion on Drug Safety, Informa Healthcare, 2021, 20 (10), pp.1247-1256. ⟨10.1080/14740338.2021.1939304⟩. ⟨hal-03406940⟩

Share

Metrics

Record views

18